KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer.

Felix Y Feng, Matthew R Smith, Fred Saad, Pooya Mobadersany, Shaozhou K Tian, Stephen S F Yip, Joel Greshock, Najat Khan, Margaret K Yu, Sharon McCarthy, Sabine D Brookman-May, Ariel B Bourla, Tamara Todorovic, Rikiya Yamashita, Huei-Chung Huang, Trevor J Royce, Timothy N Showalter, Jacqueline Griffin, Akinori Mitani, Andre Esteva, Eric J Small

JCO Precis Oncol 9 e2400653

PMID39889245
PMCID-
DOI10.1200/PO-24-00653
发表日期2025-01-31
入排依据:This is a post-hoc subgroup/biomarker analysis (digital pathology-based AI) of the primary SPARTAN trial. While it reports time-to-event outcomes for a drug-containing arm, it is not the original primary efficacy report of the randomized trial, but an exploratory biomarker study within it.
摘要

摘要

PURPOSE: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histopathology-based multimodal artificial intelligence (MMAI) algorithm to estimate clinical outcomes in SPARTAN. METHODS: Patients with available hematoxylin and eosin-stained slides from the primary tumor were included. Histopathology slides were digitized. MMAI scores ranging from 0 to 1 were generated from digital histopathology and baseline clinical parameters. Patients were categorized into MMAI non-high-risk and high-risk groups using previously validated cutoffs. Kaplan-Meier estimates were calculated for metastasis-free survival (MFS), second progression-free survival (PFS2), and overall survival (OS); comparisons were performed using Cox proportional hazards regression for treatment arms and MMAI risk. The interaction between treatment arm and risk group was evaluated using a Cox proportional hazards model. RESULTS: The study included 420 evaluable patients after excluding those with missing clinical data or inadequate histopathology images. Of these, 63% (n = 266) were MMAI high risk and 37% (n = 154) were non-high risk. MMAI risk score was associated with shorter MFS (hazard ratio [HR], 1.72; P < .005), PFS2 (HR, 1.57; P < .005), and OS (HR, 1.41; P = .02). MMAI high-risk patients receiving apalutamide demonstrated significant improvement in MFS (HR, 0.19; P < .005), PFS2 (HR, 0.47; P < .005), and OS (HR, 0.6; P = .01). The interaction between MMAI risk score and treatment for MFS (P = .01) and PFS2 (P = .03) was significant, indicating greater benefit from apalutamide treatment in MMAI high-risk patients. CONCLUSION: MMAI is a prognostic marker in nmCRPC and may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide. These results represent the first extension of an MMAI classifier to patients with castration-resistant prostate cancer, warranting additional validation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。